RESUMO
Prescription drug monitoring programs are statewide databases available to clinicians to track prescriptions of controlled medications. These programs may provide valuable information to assess the history and use of controlled substances and contribute to clinical decisionmaking in the emergency department (ED). The widespread availability of the programs raises important ethical issues about beneficence, nonmaleficence, respect for persons, justice, confidentiality, veracity, and physician autonomy. In this article, we review the ethical issues surrounding prescription drug monitoring programs and how those issues might be addressed to ensure the proper application of this tool in the ED. Clinical decisionmaking in regard to the appropriate use of opioids and other controlled substances is complex and should take into account all relevant clinical factors, including age, sex, clinical condition, medical history, medication history and potential drug-drug interactions, history of addiction or diversion, and disease state.
Assuntos
Revisão de Uso de Medicamentos/ética , Serviço Hospitalar de Emergência/ética , Medicamentos sob Prescrição/uso terapêutico , Humanos , Uso Indevido de Medicamentos sob Prescrição/prevenção & controle , Medicamentos sob Prescrição/efeitos adversosRESUMO
No disponible
Assuntos
Idoso de 80 Anos ou mais , Idoso , Feminino , Humanos , Masculino , Tradução , Revisão de Uso de Medicamentos/organização & administração , Revisão de Uso de Medicamentos/normas , Revisão de Uso de Medicamentos , Prescrições/normas , Revisão de Uso de Medicamentos/ética , Revisão de Uso de Medicamentos/legislação & jurisprudência , Revisão de Uso de Medicamentos/tendências , Prescrição Inadequada/prevenção & controle , Prescrição Inadequada/tendênciasRESUMO
In this article the authors deal with issues of drug utilisation from a clinical and policy perspective. They address the difficulties of managing drug therapy on a population level, which is known among professionals, as the problem of rational use of medicines. Various definitions and interpretations are presented and compared. This is followed by a presentation of the concerns associated with pharmaceutical marketing from a policy perspective, including the fear that the dominance of information produced by industry may lead to irrational drug use. Next, the authors review the tools for policy making including educational, managerial, and regulatory interventions. The (often overlapping) concepts of medicines management, clinical pharmacy and pharmaceutical care are then discussed to show how professionals, sometimes in collaboration with policymakers, have tackled the problem of nonrational use of medicines. The authors address the question as to whether the rational use of medicines a universal concept, whether it can be and whether it should be? They argue that, as with most concepts, the rational use of medicines must always be viewed in context. They conclude that pharmacy needs to adapt its way of thinking to include the issue of context. They point out that clinical pharmacists today already adapt their decisons to each patient and patient group. Policy-makers are encouraged to adopt a similar approach because populations as well as particular market situations vary and therefore policy solutions cannot be considered universal.